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OBJECTIVES: To compare medication treatment pat-
terns for patients who initiated on olanzapine (OLZ)
versus risperidone (RIS).
METHODS: Retrospective analysis of a large, geographi-
cally diverse claims database of insured individuals 
identiﬁed 670 enrollees who: (1) were diagnosed with
schizophrenia; (2) initiated on OLZ (n = 423) or RIS (n
= 247) monotherapy, and (3) had no use of OLZ or RIS
in one year prior-initiation. Multivariate analyses were
used to compare the OLZ and RIS groups with respect
to treatment duration and likelihood of receiving 
medication for at least 80% of days during the one-year
post-initiation, likelihood of switching between study
drugs, and likelihood of receiving concomitant treatment
for Parkinsonian symptoms. Regressions controlled for
demographics, comorbidities, and previous medication
use patterns.
RESULTS: Compared to RIS (mean dose = 3.32mg/day),
patients treated with OLZ (mean dose = 10.45mg/day)
experienced a 29.4% increase in treatment duration (162
days vs. 213 days; p < 0.0001), a higher probability of
receiving medication for at least 80% of days (Odds Ratio
= 2.057, p = 0.0002), a decrease in the probability of 
concomitant use of anti-Parkinsonian medications (Odds
Ratio = 0.639; p = 0.0284). Patients who initiated on
OLZ were less likely to switch to RIS than vice versa
(Odds Ratio = 0.275; p < 0.0001).
CONCLUSIONS: Compared to RIS, patients treated
with OLZ experienced a longer duration of therapy, an
increased likelihood of receiving 80% of days of therapy,
a decreased likelihood of concomitant use of anti-
Parkinsonian agents, and a lower probability of switch-
ing among medications of interest.
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Studies have shown that systemic absorption of oph-
thalmic beta-blockers (OBBs) can potentially cause severe
systemic side effects.
OBJECTIVES: To evaluate the use of OBBs among
patients with a contraindication or precaution against its
use.
METHODS: We conducted a retrospective analysis of
pharmacy and medical claims data from a West Coast
health plan. Patients receiving a prescription for oph-
thalmic betaxolol, carteolol, levobunolol, metipranolol,
or timolol between 7/1/98 and 6/30/00 were included in
this study. Study cohorts were identiﬁed based upon the
ﬁrst OBB agent received and were followed for 180 days.
Patients receiving prescriptions for different OBBs that
were more than 180 days apart were categorized as
having two episodes of care. OBBs are contraindicated 
in patients with sinus bradycardia/persistent severe 
bradycardia, asthma, COPD, and greater than ﬁrst degree
heart block. OBBs have precautions against use in 
patients having diabetes mellitus, congestive heart 
failure, Raynaud’s phenomenon, or using oral beta-
blockers. OBB use was deﬁned as inappropriate if used
simultaneously with oral beta-blockers, within 15 days of
heart block diagnosis, or within 6 months of the other 
conditions.
RESULTS: A total of 9,094 unique patients contributed
9,294 episodes of care. The percentage of patients with a
contraindication or precaution against OBB use, respec-
tively, was 12.7% and 20.9% (betaxolol: 19.9% with
contraindication, 22.7% with precaution; carteolol:
9.7%, 20.9%; levobunolol: 13.0%, 21.5%; metipra-
nolol: 9.2%, 21.5%; timolol: 10.7%, 20.3%). Overall,
29.6% of patients had at least one contraindication or
precaution against OBB use, and 7.6% had multiple 
contraindications and/or precautions.
CONCLUSION: Nearly three out of ten patients who
received an OBB had a contraindication or precaution
against its use. Further research is needed to determine
the incidence of clinically signiﬁcant adverse effects from
prescribing OBBs in these patient populations, and to
identify alternative glaucoma medications that may be
more appropriate for these patients.
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OBJECTIVES: Current treatments for non-melanoma
skin cancer (NMSC) can be problematic when lesions are
in cosmetically sensitive sites. Patients may also be unsuit-
able for standard therapies for other reasons. Cosmetic
procedures are therefore common. Methyl aminolevuli-
nate (Metvix) photodynamic therapy (MAL PDT) has
comparable lesion response rates and superior cosmetic
outcomes in such patients. The aim of this study was to
estimate the mean total costs of treatment to the UK
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health care system for methyl aminolevulinate (MAL)
PDT compared with a set of current treatment options.
METHODS: A decision-analytic approach was adopted
in which treatment pathways were deﬁned for both MAL
PDT and the current treatment options. The model
follows patients presenting with basal cell carcinoma
(BCC) or actinic keratosis (AK) through up to three lines
of treatment, accounting for the associated health care
costs. Epidemiological and GP referral/treatment para-
meters were determined from a survey of GPs. Treatment
modality and reconstructive surgery parameters were
determined from a survey of UK specialists familiar with
the treatment of NMSC. Further model parameters were
determined from an extensive literature review of the 
clinical data.
RESULTS: The surveys indicated that simple lesion 
excision is currently the favoured treatment modality 
for difﬁcult-to-treat BCC. For patients with difﬁcult-
to-treat AK, 5-ﬂuorouracil is currently the favoured 
treatment. In addition, the surveys showed that a large
number of patients undergoing lesion excision require
costly reconstructive surgery. The decision-analytic model
found MAL PDT had higher initial costs, but had cost-
offsets due to reduced requirement for reconstructive
surgery.
CONCLUSIONS: Higher initial costs associated with
MAL PDT are offset by savings from reduced recon-
structive surgery. Improved cosmetic outcome and
reduced need for surgery are also likely to impact on
patients’ treatment preferences and on quality of life.
PES3
TOPICAL CORITCOSTEROID AND PHYSICIAN
VISIT UTILIZATION AND COSTS IN PATIENTS
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OBJECTIVE: Describe the utilization and costs of topical
corticosteroids (TCS) and physician visits in patients 
with atopic dermatitis (AD) from the third party payer
perspective.
METHODS: Data were extracted from Medstat’s 
MarketScan, a proprietary claims database, which
includes people who received pharmacy and medical ben-
eﬁts from various managed care organizations (MCOs).
We identiﬁed patients with continuous pharmacy cover-
age throughout 1999 with at least one ICD-9 code for
AD (691.8 or 692.9). TCS utilization was assessed as the
average number of prescriptions, average number of 
prescriptions per patient, and average quantity dispensed.
Drug costs are reported as the average AWP and average
MCO payment. All drug information was stratiﬁed by
brand/generic status. Physician visits were identiﬁed 
as either generalist or specialist. Costs for physician 
visits were identiﬁed from the 1999 PMIC physician fee
schedule.
RESULTS: 71,025 people were identiﬁed with AD, and
the estimated overall prevalence was 3.22%, and 3.93%
for patients 18 years of age or younger. Of these patients,
12.9% were treated with brand name TCS, at 1.5 pre-
scriptions (42 grams each) per patient per year (pppy),
and 12.9% were treated with generic TCS, at 1.5 pre-
scriptions (64 grams each) pppy. Brand name TCS 
prescribed to those £18 had an average AWP of $34.46
and an average MCO payment of $21.36. The corre-
sponding ﬁgures for generic TCS were $17.62 and
$10.09. Total MCO payments for TCS were $3.65 per
AD patient for 1999. Patients £18 years visited a gener-
alist approximately 1.2 times per year and specialist 1.4
times per year. Total physician visit costs were estimated
to be $172.60 per patient in 1999.
CONCLUSIONS: Despite the availability of generic TCS,
50% of prescriptions were for brand name products.
However, overall, TCS costs are small relative to the costs
for physician visits.
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Informal caregivers are individuals who provided uncom-
pensated care for their families and/or friends.
OBJECTIVES: To examine the impacts of visual impair-
ment (VI) on costs associated with informal caregivers in
the U.S. elderly population.
METHODS: We used data from the “Helper” ﬁle in 
the Asset and Health Dynamics Among the Oldest Old
(AHEAD) Wave I, a biennial prospective panel data 
collected for noninstitutionalized persons aged 70 years
old and over between 1993 and 1994. Time spent by the
informal caregivers (e.g., frequency of care per week,
hours spent per day) was combined with hourly wage
rates to calculate costs associated with informal care. VI
was approximated by those who reported poor eyesight
or legally blind in a self-reported health condition ques-
tion. Multivariate regression models were used to evalu-
ate the impacts of VI on informal care-givers’ costs while
accounting for confounding factors such as demograph-
ics and comorbidities.
RESULTS: Use of informal caregivers was found in
64.2% of the visually impaired group, almost three times
that of the visually unimpaired group (22.88%). On
average, the visually impaired group received 20.5 hours
of care weekly from informal caregivers, compared with
a weekly average of 5.3 hours in the visually unimpaired
group. The estimated monthly cost associated with 
informal caregivers was $980 for the visually impaired
and $253 for the visually unimpaired. Using the loga-
rithm of monthly costs as the dependent variable, the
